FR2145402A1 - Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia - Google Patents

Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia

Info

Publication number
FR2145402A1
FR2145402A1 FR7125666A FR7125666A FR2145402A1 FR 2145402 A1 FR2145402 A1 FR 2145402A1 FR 7125666 A FR7125666 A FR 7125666A FR 7125666 A FR7125666 A FR 7125666A FR 2145402 A1 FR2145402 A1 FR 2145402A1
Authority
FR
France
Prior art keywords
magnesium
acetylglycinate
hypomagnesaemia
hexahydrate
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7125666A
Other languages
French (fr)
Other versions
FR2145402B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALLARD ANDRE FR
Original Assignee
ALLARD ANDRE FR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALLARD ANDRE FR filed Critical ALLARD ANDRE FR
Priority to FR7125666A priority Critical patent/FR2145402A1/en
Publication of FR2145402A1 publication Critical patent/FR2145402A1/en
Application granted granted Critical
Publication of FR2145402B1 publication Critical patent/FR2145402B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Magnesium acetylglycinate hexa-hydrate, for the treatments of hypomagnesaemia without the side-effects associated with the use of magnesium chloride and magnesium orotate-lactate. The oral mouse LD50 is 17.5g/kg. Blood levels in rabbits are slightly lower than those after MgCl2 but better than after magnesium lactate. Clinical effects are good and the salt was well tolerated. Prepd. by neutralization of aceylglycine with MgCO3.
FR7125666A 1971-07-13 1971-07-13 Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia Granted FR2145402A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7125666A FR2145402A1 (en) 1971-07-13 1971-07-13 Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7125666A FR2145402A1 (en) 1971-07-13 1971-07-13 Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia

Publications (2)

Publication Number Publication Date
FR2145402A1 true FR2145402A1 (en) 1973-02-23
FR2145402B1 FR2145402B1 (en) 1974-09-06

Family

ID=9080306

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7125666A Granted FR2145402A1 (en) 1971-07-13 1971-07-13 Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia

Country Status (1)

Country Link
FR (1) FR2145402A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
EP0130644A1 (en) * 1983-06-30 1985-01-09 Continental Pharma, Inc. Use of 2-Pentanoylaminoacetic acid and salts thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
EP0130644A1 (en) * 1983-06-30 1985-01-09 Continental Pharma, Inc. Use of 2-Pentanoylaminoacetic acid and salts thereof
US4562205A (en) * 1983-06-30 1985-12-31 Continental Pharma Inc. Derivatives of 2-aminoacetic acid

Also Published As

Publication number Publication date
FR2145402B1 (en) 1974-09-06

Similar Documents

Publication Publication Date Title
GB1362220A (en) Face steamer
BE764305A (en) THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMATORY CONDITIONS.
ZA72423B (en) Improvements in or relating to the treatment of diseases of the skin or mucosa
FR2145402A1 (en) Magnesium acetylglycinate hexahydrate - for treating hypomagnesaemia
ES404616A1 (en) Method of suppressing seborrhea
Harrow The effects of psychodrama group therapy on role behavior of schizophrenic patients
FR2085630A1 (en) Vincamone compsn - having vasodilator ganglioplegic and antihistamine activity
ES407058A1 (en) Flavoring agent
ZA71586B (en) Treatment of brine
ZM17172A1 (en) Treatment of titanium
GB572878A (en) Polymers and copolymers from chloroacrylophenones
Price The Relief of Acute Pleuritic Pain by Intercostal Nerve Block
AU3317971A (en) The use of diphenylsulfones inthe treatment of mareks disease
IT945473B (en) IMPROVEMENTS IN THE TREATMENT OF CHLORIDE SOLUTIONS CONTAINING MIXED METALLIC CHLORIDES
ZA711301B (en) Treatment of titanium dioxide
TRAVELL Early Relief of Chest Pain by Ethyl Chloride Spray in Acute Coronary Thrombosis: Case Report
ZA716294B (en) Treatment of leather
BE772342A (en) SALTS OF CHONDROITINE SULPHATE, THEIR PREPARATION METHODS AND THEIR THERAPEUTIC USE
SU843970A1 (en) Laryngotome
GB1300694A (en) Biocidal composition and disinfecting method
FR2022085A1 (en) Improving tolerance of x-ray films to safe - lights
FR2168924A2 (en) Hetacephalexin compsns - for human and veterinary antibacterial therapy, and as foodstuff additive
USD224974S (en) Game puzzle
USD217497S (en) Dental light or the like
Chabin Results of clinical evaluation of conservative orthopedic treatment of fractures of the body of the mandible

Legal Events

Date Code Title Description
ST Notification of lapse